Key result
Six circulating m6A regulators including METTL3 emerge as novel AMI diagnostic biomarkers with ~0.77 AUC.
Why the study?
Acute myocardial infarction is a major contributor to death, prompting exploration of circulating biomarkers for diagnosis based on the immunological microenvironment and m6A RNA methylation regulation.
Can m6A RNA methylation regulators serve as circulating biomarkers for the diagnosis of acute myocardial infarction?
Case-Control (n=64)
No
Can m6A RNA methylation regulators serve as circulating biomarkers for the diagnosis of acute myocardial infarction?
Effect estimate: AUC 0.772 (95% CI 0.626-0.917)
p-value: p=0.003
Six m6A RNA methylation regulators were identified as potential novel circulating biomarkers for the diagnosis of acute myocardial infarction.
May aid AMI diagnosis upon validation; extends epigenetic biomarker research to acute coronary syndromes.
Purpose: Acute myocardial infarction (AMI) is a major contributor to death. The purpose of this study is to explore circulating biomarkers for AMI diagnosis from the perspectives of immunological microenvironment and N6-methyladenosine (m6A) RNA methylation regulation. Patients and Methods: The GSE59867 dataset was used to download platform and probe data for conducting differential analysis of m6A regulators. A diagnostic nomogram was created utilizing the random-forest method and evaluated for predictive power. m6A-related gene patterns were identified, and their immune microenvironment characteristics were analyzed. Peripheral blood samples were obtained for validation in patient-based investigations using RT-qPCR. The association between m6A regulators and clinical parameters was examined via Spearman correlation analysis. Results: With a predictive nomogram model developed using key m6A regulators, two distinct m6A subtypes were identified, showing significant variations in infiltrating immunocyte abundance. In confirmation of the model prediction, examination of patient blood identified METTL3, WTAP, RBM15, ALKBH5, FTO, and FMR1 as novel circulating biomarkers for AMI diagnosis. METTL3 and FTO were identified as promising biomarkers for AMI given that they showed a positive correlation with left ventricular ejection fraction. Conclusion: The study identified six m6A regulators as circulating biomarkers for AMI diagnosis and suggested a potential role for m6A-mediated immune cell infiltration in the pathogenesis of AMI.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2025) conducted a case-control in Acute Myocardial Infarction (n=64). m6A RNA methylation biomarkers (METTL3, WTAP, RBM15, ALKBH5, FTO, FMR1) vs. Control patients with no diagnostic stenosis was evaluated on Diagnosis of Acute Myocardial Infarction using METTL3 (AUC 0.772, 95% CI 0.626-0.917, p=0.003). Six m6A regulators, including METTL3 (AUC 0.772), were identified as novel circulating biomarkers for the diagnosis of acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: